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Human adrenomedullin (AM) is a 52 amino acid peptide, which
shares homology with the calcitonin gene-related peptide. Over-
expression of AM in the prostate carcinoma cell line PC-3 results
in growth inhibition with a 20% (for human AM) and 35% (for rat
AM) increase in doubling time compared to parental or mock-
transfected cells. We demonstrate by gene expression profiling
that AM overexpression results in the dysregulation of approxi-
mately 100 genes. Examples of such genes include many involved
in the formation of the cytoskeleton, cell adhesion and the extra-
cellular matrix, as well as regulators of the cell cycle and apopto-
sis, cytokines and transcription factors. Several genes related to
cell growth arrest, such as GADD45, IGF-BP6 and RUNX-3, are
upregulated by AM. Interestingly, interleukin-13 receptor 2 (IL-
13R2) transcripts were significantly increased in clones overex-
pressing AM, which was confirmed by semiquantitative RT-PCR
analysis. In addition, PC-3 cells treated with AM showed an
overexpression of IL-13R2, which was abolished when cells were
preincubated with an anti-AM blocking antibody. When PC-3
cells overexpressing AM and the IL-13R2 were treated with the
highly specific IL13-PE38 cytotoxin, which binds to this receptor,
a concentration-dependent inhibition of protein synthesis was ob-
served. The IC50 (concentration of cytotoxin inhibiting protein
synthesis by 50%) ranged from 1 to 4 ng/ml. This cytotoxicity was
specific as it was neutralized by the excess of IL-13 and confirmed
by clonogenic assays. This study describes a novel AM-induced
mechanism of tumor sensitization through the upregulation of
functional IL-13R2 chain, an ideal target for the highly specific
recombinant chimeric cytotoxin IL13-PE38.
© 2004 Wiley-Liss, Inc.
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Prostate carcinoma is the second leading cause of cancer mor-
tality among men in the United States.1 The 5-year relative sur-
vival rate for the patients whose tumors are diagnosed with local or
regional disease approaches 100%, but the relative 10- and 15-year
survival rates are reduced to 75% and 54%, respectively.1 Al-
though localized prostate cancer may be successfully treated, 70%
of patients eventually progress and develop metastasis. The current
nonsurgical therapeutic regimens for treating prostate carcinoma
include radio-, hormonal- and chemotherapy, as well as a combi-
nation of these regimens, depending on specific circumstances of
the patient. The limited success of treating particular forms of
prostate cancer requires that additional targets for therapy be
identified and tested.
Expression of adrenomedullin, an amidated peptide that was
originally isolated from human pheochromocytoma,2 has been
documented in both the human and rat prostate,3 human prostate
carcinoma4 and prostate cancer cell lines,4 where it has been
suggested that adrenomedullin (AM) may act as an autocrine/
paracrine factor. Human AM consists of 52 amino acids (50 amino
acids for rat AM) and shares certain homology with the calcitonin
gene-related peptide (CGRP). AM appears to be ubiquitously
expressed2,5 and can perform a variety of functions, including
vasodilatation, bronchodilation, hormone secretion control, renal
homeostasis and regulation of cell growth.5–7 Some cell types
are stimulated to proliferate by AM,7,8 whereas other cell
types are growth-inhibited.9 The calcitonin receptor-like receptor
(CRLR), in conjunction with receptor activity-modifying protein-2
(RAMP-2) and -3 (RAMP-3), functions as AM receptors in nu-
merous cell types.5 Although elevation of cAMP levels is the most
common intracellular event that occurs as a consequence of AM
receptor activation,10 this peptide can also act through calcium11
and cGMP12 signaling. AM also interferes with Ca channels
and interacts with cytokines.13–16
Consistent with this hypothesis, inflammatory cytokines such as
TNF and IL-1 increase AM levels in vascular smooth muscle
cells.17 AM also stimulates IL-6 production in fibroblasts.18 AM
expression and secretion is stimulated by hypoxia, lipopolysaccha-
ride and NO.17,19,20
In the context of cancer, AM seems to play a growth-modulatory
effect in prostate carcinoma. To investigate the role of AM in
prostate carcinoma, we previously generated PC-3 cell line clones,
which express high levels of AM. Overexpression of AM in PC-3
cells resulted in cell growth inhibition in vitro and in vivo.21 To
discover genes potentially responsible for AM action in PC-3 cells,
in this study we performed gene expression profiling using cDNA
microarrays with approximately 11,000 features. By this analysis,
we identified numerous genes whose levels of expression appear to
be altered by AM. Here we focused on one gene. Interleukin-13
receptor 2 (IL-13R2) is highly upregulated by adrenomedullin.
Its upregulation was confirmed by conventional RT-PCR studies.
Finally, we demonstrate that upregulated IL-13R2 gene results in
gene transcription and translation of IL-13R2 protein, which is
functional. These findings have important implications for under-
standing the regulation of IL-13R2 and for cancer therapy tar-
geted to the IL-13R2.
Material and methods
Recombinant proteins and cell culture
Recombinant IL-13 and IL13-PE38 were expressed and purified
as previously reported.22 IL13-PE38 is comprised of IL-13 fused to
domain II and III of Pseudomonas exotoxin (PE).
We have previously generated and characterized PC-3 clones
overexpressing AM or clones carrying the empty pcDNA 3.1
expression vector.21 PC-3 cells were grown in RPMI-1640 me-
dium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal calf
serum (FCS), 1 mM sodium pyruvate, 10 mM HEPES buffer,
2 mM glutamine, 50 U/ml penicillin G sodium and 50 g/ml
streptomycin sulfate in 5% CO2 atmosphere tissue culture incuba-
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tor. AM-transfected or mock-transfected clones were cultured in
the same media containing 150 g/mL Hygromycin B (Invitrogen)
to maintain selection of AM-expressing clones. Since the overex-
pression of rat AM resulted in more effective growth inhibition
than for clones containing human AM,21 we included both human
and rat AM-transfected clones in this study. Clones used in the
present work were AM3.2M and AM3.2B (PC-3 clones that over-
express human AM), AM15 and AM17 (clones that overexpress
rat AM) and mock-2 (a PC-3 clone carrying the empty vector).
RNA isolation and cDNA microarray analysis
Total RNA was isolated from the clones in culture using the
RNeasy Mini Kit (Qiagen, Valencia, CA) according to the manu-
facturer’s protocol, with the additional step of DNase treatment.
The quality of the total RNA isolated was determined by running
aliquots on 1% agarose gel in TAE. The Incyte human UNIGEM
v2px set of cDNA clones containing about 11,000 features was
arrayed on poly-L-lysine-coated glass slides at the National Cancer
Institute Advanced Technology Center. The gene list is available at
http://nciarray.nci.nih.gov.
Preparation of the cDNA-labeled probes was performed using
the Micromax system (NEN Life Science Products, Boston, MA);
20 g of total RNA from both the reference sample (PC-3 cell
line) and the experimental samples (AM3.2M, AM3.2B, AM15,
AM17 and mock-2) were reverse-transcribed in the presence of
Cyanine 3-dUTP and Cyanine 5-dUTP, respectively, for 1.5 hr at
42°C. The labeled cDNAs were filtered through a Microcon
YM-30 column (Millipore, Bedford, MA). The slides were prehy-
bridized in a solution of 5 SSC, 0.1% SDS and 1% BSA for 1 hr
at 42°C. Following the prehybridization, the slides were rinsed in
H2O, isopropanol, and dried by centrifugation at 50g for 3 min.
Two L (10 g) of COT-1 DNA (Invitrogen), 2 L (16 g) of
Poly-A (Amersham Pharmacia Biotech, Cambridge, U.K.) and
2 L (4 g) of yeast tRNA (Sigma, St. Louis, MO) were added to
the cDNA probe solution for a final volume of 10 L. This was
mixed with an equal volume of hybridization solution (50% form-
amide, 10 SSC, 0.2% SDS) and placed onto the microarray slide
for hybridization at 42°C for 16 hr.
Following hybridization, slides were washed sequentially for
3 min in solutions with increasing stringency: 2  SSC, 0.1%
SDS; 1  SSC, 0.1% SDS; 0.5  SSC; and 0.01  SSC. Imme-
diately after washing, slides were dried by centrifugation as de-
scribed earlier and scanned using a Genepix 4000Bscanner (Axon
Instruments, Foster City, CA).
Three to five arrays for each PC-3 clone were performed. Genes
with a 2-fold change in the geometric means of the ratios between
the AM-expressing cells or empty vector were filtered and ana-
lyzed using hierarchical clustering. Filtered named genes were
classified using GeneCards (http://bioinformatics.weizmann.ac.il)
and extensive review of the literature.
To discard systematic errors due to dye incorporation, reverse-
fluor microarray analysis was performed. In these cases, PC-3
parental cell line cDNA (reference) was labeled with Cy-5,
whereas cDNAs from PC-3 clones were labeled with Cy-3. Ex-
tensive analysis of reverse-fluor labeling in our laboratory using
the same arrays has revealed that dye bias is insignificant.23
Reverse transcriptase-polymerase chain reaction (RT-PCR)
Total RNA from parental PC-3 cells, mock-2 and AM15,
AM17, AM3.2M and AM3.2B clones, isolated with the RNeasy
Mini Kit (Qiagen), were used for RT-PCR analysis of the IL-
13R2 chain and AM receptors. -actin mRNA amplification from
these samples served as an internal control. The optimal RT-PCR
conditions for the IL-13R2 chain and the primers have been
published previously.24,25 The sequence of the primers and the
PCR conditions used for the amplification of AM receptors are
listed in Table I. Five hundred ng of total RNA from various cell
clones were reverse-transcribed using the RNA PCR kit (Perkin
Elmer, Norwalk, CT) as per the manufacturer’s instructions.
Ten l of reverse-transcribed products were amplified for 30 cy-
cles using GeneAmp PCR system 9700 (Applied Biosystem, Per-
kin Elmer). The amplification products were resolved on a 2%
agarose gel and stained with ethidium bromide. The band intensi-
ties of RT-PCR products for IL-13R2 and -actin were evaluated
using a fluorescence densitometer (Molecular Dynamics, Sunny-
vale, CA). The relative fluorescence intensity was determined by
dividing the intensity of IL-13R2 chain mRNA by the density of
-actin band and expressed as the ratio of relative fluorescence
units (RFUs).
Real-time RT-PCR analysis
PCR primer sequences for human/rat adrenomedullin and 28s
ribosomal RNA (for normalization) used in real-time RT-PCR anal-
ysis were as follows: AM sense primer 5-TACCGCCAGAGC-
ATGAACCA-3; AM antisense primer 5-TGCCGTCCTTGTCTT-
TGTCT-3; 28S rRNA sense 5-GGGTGGTAAACTCCATCTAA-
3; 28S rRNA antisense 5-AGTTCTTTTCAACTTTCCCT-3.
Melting curves and gel analyses were performed to confirm the
presence of single amplified species. Quantitative analysis of gene
expression was carried out using SYBR PCR Core Reagents (PE
Biosystems, Warrington, U.K.) and a Bio-Rad I-Cycler IQ real-time
detection system (Bio-Rad, Richmond, CA). The level of gene ex-
pression was calculated after normalizing samples to the 28s rRNA
level in each sample and is presented as relative units. Samples were
analyzed in triplicate.
Expression of IL-13R2 after AM neutralization
To determine if neutralization of AM will result in a downregu-
lation of IL-13R2, we cultured 80% confluent PC-3 cells in
RPMI supplemented with 1% FBS in the presence of human AM
(cell-free supernatant obtained from an AM-overexpressing PC-3
cell clone for 48 hr with or without preincubation with blocking
anti-AM antibody rabbit serum; 1:100 dilution; a generous gift
from Dr. L. Ouafik26) for 1 hr, followed by additional 48-hr
incubation in the presence of human AM. Controls included the
incubation of PC-3 cells with or without AM plus the rabbit IgG
isotype antiserum. Total RNA was analyzed for IL-13R2 expres-
TABLE I – PRIMER SEQUENCES AND CONDITIONS FOR THE DETECTION OF AM RECEPTORS
Gene name Genbank no. Primer Sequence (5 3 3) Position Meltingtemperature
CRLR U17473 S TGCTCTGTGAAGGCATTTAC 1,159 63AS CAGAATTGCTTGAACTCTC 1,655
RCP AF073792 S TGGGCAAGAGAACTTGAACA 111 60AS TTCCACGATCAGCTGGATCT 306
RAMP-1 NM005855 S GAGACGCTGTGGTGTGACTG 189 61AS TCGGCTACTCTGGACTCCTG 614
RAMP-2 AJ001015 S GGACGGTGAAGAACTATGAG 235 60AS ATCATGGCCAGGAGTACATC 517
RAMP-3 AJ001016 S TGGAAGTGGTGCAACCTGTC 189 63AS CACGGTGCAGTTGGAGAAGA 347
-actin BC001301 S TCCATCGTCCACCGCAATG 1,169 55AS TTGTGAACTTTGGGGGATGCTC 1,398
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sion by RT-PCR analysis using the same conditions described
above. The amplified RT-PCR products were processed and quan-
tified as described above.
Protein synthesis inhibition assay
The cytotoxic activity of IL13-PE38 was determined by a pro-
tein synthesis inhibition assay as previously described.25,27 Protein
synthesis inhibition directly correlates with cell death.27 Briefly,
104 PC-3 clones were cultured in leucine-free medium with or
without various concentrations of IL13-PE38 for 20–22 hr at
37°C. For competition studies, cells were preincubated with IL-13
(2 g/ml) for 40 min at 37°C prior to the addition of IL13-PE38 to
the cells. Then, 1 Ci of [3H]-leucine (NEN Research Products,
Wilmington, DE) was added to each well and cells were incubated
for an additional 4 hr. Cells were harvested and radioactivity was
measured by counting the filter mat using a -plate counter (Wal-
lac, Gaithersburg, MD).
Colony formation assay
In vitro cytotoxic activity of IL13-PE38 on PC-3 clones was
also evaluated by a colony formation assay.28 Cells were harvested
from culture, washed and resuspended in complete medium. Cells
were plated in quadruplicate in 100 cm2 Petri dishes (Falcon;
Becton Dickinson, Lakeridge, NJ) and cultured overnight. The
number of cells per plate was selected so that more than 100
colonies were obtained in the control group. The cultures were
then incubated with IL13-PE38 (0–1,000 ng/ml) for 10 days at
37°C in a humidified CO2 incubator. After removing the medium,
the colonies were washed with PBS and stained with 0.025%
crystal violet in 25% ethyl alcohol. Colonies with 50 or more cells
were scored. The number of colonies observed in IL13-PE38-
treated cultures was expressed as a percentage of the number of
colonies formed in untreated control cultures.
Results
Inhibition of cell growth by AM
Quantitative analysis of AM mRNA levels (normalized to 28s
rRNA levels) was performed by real-time RT-PCR to confirm the
overexpression of AM in the stably transfected PC-3 cell clones.
Significantly higher levels (approximately 100-fold increase) of
AM mRNA were found in AM-transfected cell clones compared to
the parental cell line or the clone containing the empty vector
(mock-2) (Fig. 1). Protein levels of AM in the conditioned media
of these clones assessed by radioimmunoassay demonstrated AM
levels of 16 pg/mL in the PC-3 parental cell line, whereas clones
overexpressing AM had approximately 10-fold higher levels.21
We have compared the average doubling time for all 4 clones
that overexpress human and rat adrenomedullin with that of the
parental cell line and the mock-transfected clone. The doubling
time of parental PC-3 cells was determined to be 18  2.1 hr,
whereas that of PC-3 cells overexpressing human AM was 22 
1.6 hr and 28 2.9 hr for cells overexpressing rat AM. Our results
demonstrate that AM can significantly inhibit the proliferation of
PC-3 cells.
Expression of AM receptors
The AM receptor complex CRLR/receptor component protein
(RCP)/RAMP was analyzed in PC-3 cells and the clones that were
transfected with AM by RT-PCR. Parental PC-3, mock-transfected
and AM-overexpressing cells expressed CRLR, RCP and RAMP-2
(Fig. 2). No expression of RAMP-1 and RAMP-3 was detected.
The expression of CRLR and RAMP-2 seemed to be higher in the
cell clones overexpressing AM. For RAMP-2, a band of the
FIGURE 1 – Relative expression of AM in PC-3 parental cells and
PC-3 clones stably transfected with human AM (AM3.2M and
AM3.2B), rat AM (AM15, AM17), or empty vector (mock-2) as
measured by quantitative real-time RT-PCR. Values were normalized
to the expression of 28s rRNA. The expression of AM mRNA in
clones transfected with the AM gene is approximately 100-fold higher
than that compared to the parental and mock-transfected cells.
FIGURE 2 – Expression of AM re-
ceptors in PC-3 parental cells and
PC-3-transfected cells. CRLR, RCP
and RAMP-2 are expressed in these
cells. RAMP-1 and RAMP-3 are not
expressed. For RAMP-2, the ex-
pected band (283 bp) plus another
band that might correspond to an
alternative spliced form (415 bp)
were identified.
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expected size (283 bp) plus another band of 415 bp that could
correspond to an alternative spliced form29 were identified. Bands
were sequenced to ensure their identities.
Changes in gene expression profiles associated with AM
overexpression in PC-3 cells
In order to identify changes in gene expression, which could be
associated with the inhibition of PC-3 cell growth by AM, we
performed cDNA microarray experiments. This analysis identified
approximately 100 genes whose expression was altered by AM
using selection criteria of at least a 2-fold change in expression in
at least 3 of the arrays. Hierarchical cluster analysis revealed that
both clones overexpressing human AM had very similar gene
expression patterns. Clone AM15 overexpressing rat AM exhibited
a very similar expression profile to that of the clones expressing
FIGURE 3 – Hierarchical clustering of gene expression patterns in PC-3 clones overexpressing AM or carrying the empty vector
pcDNA3.1 (mock-transfected). PC-3 clones overexpressing human AM (AM3.2M and AM3.2B) demonstrated similar gene expression
profiles and clustered together. Clones overexpressing rat AM (AM15 and AM17) clustered separately from cells expressing human AM,
although gene expression profiles were similar (especially for clone AM15). IL-13R2 and IL-8 are examples of upregulated genes and
tenascin-C of a downregulated gene in all of the cell lines. Few changes were observed in the empty vector-transfected clone.
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human AM, while the second rat cell line clone AM17 did not
show as extensive an overlap (Fig. 3).
Examples of genes upregulated in all the PC-3 clones overex-
pressing AM were the cytokine-related genes interleukin-13R2
and interleukin-8. An example of a downregulated gene was the
adhesion-related gene tenascin-C (Fig. 3). In contrast to the clones
overexpressing AM, only 6 genes exhibiting a 2-fold change in
expression were found in the clone carrying the empty vector
compared to the parental PC-3 cell line.
Sixty-one genes were found to be consistently dysregulated in
all of the AM-overexpressing PC-3 clones compared to the paren-
tal cell line. These genes were classified according to their pre-
sumed functions (Table II), including genes involved in extracel-
lular matrix composition, cell cycle/apoptosis, tumor-related
cytokines, cytoskeleton, adhesion proteins and transcription fac-
tors. Interestingly, AM upregulated the expression of genes asso-
ciated with cell growth arrest, including GADD45, IGF-BP6, STK-
17, 5 nucleotidase and TNF-related proteins. These results are
coincident with our observations that cell proliferation is reduced
in PC-3 cells overexpressing AM compared to parental PC-3 cells.
Overexpression of AM in PC-3 cells also resulted in dys-
regulation of expression of extracellular matrix-related proteins
(Table II). Some of the upregulated genes belong to the urokinase-
type plasminogen activator superfamily. Overexpression of AM in
PC-3 cells notably upregulated 2 of the Runt family members of
transcription factors, RUNX-1 and RUNX-3. These transcription
factors play an important role in cell growth arrest. These data are
in keeping with our results in PC-3 cells and suggest that AM-
mediated cell growth inhibition might be related to the upregula-
tion of RUNX-3.
Six genes were found dysregulated (2-fold increase or decrease)
in mock-transfected PC-3 clones compared to the PC-3 parental
cell line. These genes were midkine (clone ID 940845), aldehyde
dehydrogenase 1-A3 (clone ID 2884153), milk fat globule-EGF
factor 8 (clone ID 1319020), interferon-induced transmembrane-3
(clone ID 2949427), zygin-1 (clone ID 2844322) and tropomyo-
sin-2 (clone ID 3176845). The alteration in expression of these
genes probably results from the introduction of the pCDNA3.1
vector into the PC-3 cells. However, since we only studied one
such clone, other random factors could be involved.
Overexpression of adrenomedullin enhances expression of
IL-13R2 mRNA in PC-3 cells
AM-overexpressing cells demonstrated increased mRNA expres-
sion for IL-13R2, a high-affinity specific receptor for IL-13. IL-13 is
a predominantly Th-2 cell-derived pleiotropic immune regulatory
cytokine.30 To confirm IL-13R2 gene upregulation as determined by
microarray analysis, RT-PCR analysis was performed for IL-13R2
in the various PC-3-derived cell lines. These results confirmed that,
indeed, IL-13R2 was increased in the AM-overexpressing clones
TABLE II – CLASSIFICATION OF GENES DIFFERENTIALLY EXPRESSED IN PC-3 CLONES
OVER-EXPRESSING AM COMPARED TO THE PARENTAL CELL LINE
Category Clone ID Name
Mean ratio
hAM3.2B hAM3.2M rAM15 rAM17
Extracellular matrix-
related proteins
557012 SERPIN-B2 (PAI-2) 27.7  9.1 40.2  12 95.7  33 8.7  1.9
927392 SERPIN-B8 4.0  0.6 6.2 0.8 2.8  0.1 2.5  0.7
1674454 Connective tissue growth factor 3.0  0.4 1.9 0.4 2.9  0.1 1.2  0.1
1453450 Tenascin-C (cytotactin) 2.5  0.1 2.5  0.1 10  0.1 4.1  0.1
2056158 Plasminogen activator, urokinase 4.7  0.7 5.6  0.8 5.9  0.4 4.1  0.8
5183574 Syndecan-4 1.7  0.2 3.6 0.5 2.8  0.1 1.0  0.2
Cytokines involved in
tumor growth
3360476 Interleukin-13R2 4.0  0.5 3.8 0.9 19.6  4.9 24.1 3.5
2785701 Interleukin-8 5.3  0.8 16.9  1.4 13.7 0.6 3.9 1.4
Cytoskeleton
1649959 Keratin-7 2.0  0.1 2.9 0.2 2.96  0.3 1.5 0.2
1435374 Keratin-18 2.3  0.3 2.5 0.4 2.5  0.4 1.33  0.06
Cell cycle/Growth-related
factors/Apoptosis
2352645 Amphiregulin 2.7  0.3 6.2 0.7 7.9  0.4 1.33  0.06
443631 Epiregulin 2.6  0.3 3.6 0.5 5.0  0.5 1.2  0.1
3660752 GRO-1 3.7  0.9 3.7 0.7 2.7  0.4 3.4  0.4
1702350 Growth arrest GADD45A 2.9  0.7 2.0 0.2 3.8  0.2 1.6  0.1
1968126 Growth arrest IGF-BP6 2.2  0.3 2.0 0.2 2.9  0.2 2.1  0.3
2416415 Apoptosis-inducing STK-17 3.4  0.3 3.1  0.1 2.4  0.1 2.0  0.3
2555673 Bcl-2-related protein A1 8.1  1.9 10 0.8 4.8  0.2 3.2  0.5
2205246 TNF-Receptor, member 6 2.3  0.4 2.0  0.3 2.6  0.3 2.5  0.4
1878791 TNF-alpha induced protein 3 4.3  0.7 14.8  3.8 6.8 0.7 4.2  0.6
1718651 5 Nucleotidase (CD-73) 3.3  0.3 3.5  0.6 3.8  0.3 6.3  0.4
Transcription factors
2229852 RUNX-1 2.6  0.2 3.7 0.4 2.4  0.3 1.7  0.2
885297 RUNX-3 2.7  0.2 3.6  0.6 3.4  0.1 1.6  0.06
570512 Activating transcription F1 1.5  0.1 2.8 0.1 4.4  0.5 2.0  0.4
Cell adhesion
2844322 Cell adhesion molecule FEZ-1 1.4  0.1 3.0 0.3 7.9  0.9 2.0  0.3
Others
1213932 Metallothionein-1E 1.5  0.3 3.7 0.5 6.4  0.5 4.0  0.2
2513883 Metallothionein-1L 1.6  0.5 4.7 1.1 4.0  0.1 2.07  0.9
1817434 Transketolase 2.0  0.3 1.6  0.7 1.6  0.4 2.5  0.06
1846463 Phosphate transporter,
member 1
3.6  0.3 3.4  0.5 3.8  0.3 2.0  0.1
1998510 MGC11034 2.0  0.5 5.2  0.3 2.5  0.3 4.8  0.1
382416 Cerebellar-degeneration
antigen-1
1.8  0.5 3.3  0.3 2.2  0.3 1.4  0.1
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(Fig. 4a). The fluorodensitometric results of RT-PCR products for
AM and for the -actin control were expressed as the ratio of RFUs
of the ethidium bromide-stained bands. The 2 human AM-expressing
PC-3 clones had 2.5 and 3.4 times more IL-13R2 as compared to the
parental PC-3 or empty-vector PC-3 cells. However, rat AM-express-
ing cells appeared to produce slightly higher levels of IL-13R2, with
a relative ratio of 4 (Fig. 4b). These results show a distinct pattern of
enhanced expression of IL-13R2 gene mRNA in AM-overexpress-
FIGURE 4 – Relative expression of IL-13R2 mRNA. (a) RT-PCR demonstrates low expression of IL-13R2 in the parental cell line and
cells carrying the empty vector. In contrast, clones overexpressing AM show higher expression of IL-13R2. (b) Fluorodensitometric
analysis of IL-13R2 PCR products with respect to -actin products confirms the increase in expression in AM-transfected PC-3 clones.
(c) Treatment of PC-3 cells with AM results in an upregulation of IL-13R2. Neutralization of AM by a blocking antibody produces a
downregulation of IL-13R2. The nonspecific isotype control antibody does not cause such an effect. (d) Quantitative analysis of
IL-13R2 with respect to -actin products (relative fluorescence units) in AM-neutralized cultures indicates that blocking antibody also
downregulates IL-13R2 expression.
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ing prostate tumor cells that is not dependent on the species of origin
of AM. Our results are intriguing as adrenomedullin and IL-13R2
genes are apparently nonrelated genes and have seemingly indepen-
dent biologic functions.
We next tested whether neutralization of AM resulted in a
downregulation of IL-13R2. PC-3 cells cultured in the presence
of AM (from the supernatants of AM-overexpressing PC-3 clones)
showed an increased expression of IL-13R2 compared to PC-3
cultured with supernatants of parental cells (Fig. 4c). Addition of
the AM peptide showed similar results (not shown). When PC-3
cells were preincubated with anti-AM blocking antibody and then
cultured in the presence of AM, no increase in IL-13R2 was
found. Preincubation of PC-3 cells with control rabbit IgG and
subsequent addition of AM also showed an increase in IL-13R2
mRNA (Fig. 4c). The quantification of the bands confirmed these
results (Fig. 4d). A significant increase in the RFUs for IL-13R2
was found in PC-3 cells treated with AM and AM plus IgG. When
the anti-AM blocking antibody was added, a significant decrease in
the RFUs for IL-13R2 reaching basal levels was found (Fig. 4d).
AM induction of IL-13R2 results in functionally active protein
In order to determine whether the IL-13R2 mRNA induced by
AM was translated into protein and whether IL-13R2 protein was
functionally active, we performed a cytotoxicity assay using a highly
specific chimeric fusion protein that consisted of IL-13 and a trun-
cated form of Pseudomonas exotoxin (IL13-PE38 or IL-13 cyto-
toxin). In this assay, the IL-13 cytotoxin binds to IL-13 receptor sites
on the cell surface of the tumor cells and is internalized by endocy-
tosis.18 The endocytosed protein is processed in the cytosol and then
blocks protein synthesis leading to cell death. Cytotoxic activity of
IL13-PE38 on adrenomedullin-transfected PC-3 cell lines was per-
formed using a protein synthesis inhibition assay, which correlates
with the amount of functional IL-13R2 receptors present on the
plasma membrane. We have previously documented that the activity
of this cytotoxin is highly specific, killing a variety of human tumor
cells that overexpress IL-13 receptors.25,30,31 The PM-RCC cell line
was used as a positive control, since this cell type has been shown to
express high levels of IL-13R2 protein and is extremely sensitive to
the IL13-PE38 toxin (IC50, 0.1 ng/ml; data not shown).27 Two human
and 2 rat AM-expressing PC-3 clones showed an IC50 (concentration
of IL-13 toxin causing 50% inhibition of protein synthesis) of 1–
4 ng/ml (Fig. 5). Parental and mock-transfected PC-3 cells, which
expressed low levels of IL-13R2, were minimally sensitive to IL13-
PE38 and never reached an IC50 even when a concentration of 1,000
ng/ml of cytotoxin was used. The cytotoxic effect was more pro-
nounced in the 2 PC-3 clones expressing rat AM (AM15 and AM17),
with an IC50 of 1.1 ng/ml, than for the cells overexpressing human
AM. The IC50 for the rat AM cells was similar to that for the
PM-RCC-positive control cell line (data not shown). The specificity
of IL-13 toxin-mediated cytotoxicity was further confirmed by neu-
tralization assays in the presence of excess of IL-13. In all the
AM-overexpressing PC-3 clones, IL-13 was able to neutralize cyto-
toxic activity, which indicated the specificity of the cytotoxin (Fig. 5).
The relative cytotoxic sensitivities to IL13-PE38 of the human
and rat AM-expressing PC-3 clones correlated to the differences in
their rates of cell proliferation. The stronger inhibitory effect
observed for PC-3 clones overexpressing rat AM is most likely due
to structural differences between rat and human AM.
Reduced colony formation of AM-overexpressing PC-3 cells
after treatment with IL13-PE38
In vitro assays were performed to determine whether the constitu-
tively high AM-expressing PC-3 cells were less able to form colonies
without any treatment or in response to exposure to IL13-PE38 than
PC-3 cells, which did not express high levels of AM. Table III shows
that PC-3 cells expressing either human or rat AM made significantly
less number of colonies compared to PC-3 or PC-3 mock-cells. In
addition, in the presence of IL13-PE38, AM-expressing cells made
significantly fewer colonies compared to wild-type PC-3 or mock-
transfected PC-3 cells. These results suggest that AM-expressing cells
are highly sensitive to the IL-13 cytotoxin. The range of sensitivity
(IC50) was determined to be 4–5.5 ng/ml of IL13-PE38 in human
AM-expressing PC-3 cells and 0.9 and 1.1 ng/ml in rat AM-express-
ing PC-3 cells. These results correlate well with the IC50 values
obtained by the protein synthesis inhibition assay described above.
Parental PC-3 and the mock-transfected PC-3 cell line failed to
achieve IC50 at the highest concentration of IL-13 cytotoxin. These
studies indicate that IL-13R2 chain induced by AM is functional,
making the cells extremely sensitive to IL-13 cytotoxin.
Discussion
Adrenomedullin is a widely expressed peptide that exerts a variety
of biologic functions, including vasodilatation, bronchodilation, con-
trol of hormone secretion, renal homeostasis and the regulation of cell
FIGURE 5 – IL13-PE38 cytotoxic assay. Clones overexpressing either
human (a) or rat (b) AM have impaired protein synthesis following
treatment with the IL-13 cytotoxin (IC50 ranging from 1 to 4 ng/mL). The
strongest inhibition is observed for PC-3 clones that overexpress rat AM,
with IC50 values similar to those for the positive control PM-RCC cells.
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growth.5-7 Depending on the particular cell type, AM may promote or
inhibit cell growth.8,9 Although AM is expressed in normal prostate
epithelium and prostate cancer, its function in the prostate remains
unknown. In order to investigate its potential functional role in the
prostate, we previously generated stably transfected PC-3 cells that
overexpress AM, which led to cell growth arrest and decreased rates
of proliferation in PC-3 cells.21 We have shown that PC-3 cells and
clones with overexpression of AM express receptors for AM. Both
AM and CGRP act through the same receptor known as CRLR.32
CRLR coupled to the RAMP-2 or -3 binds predominantly to AM,
whereas coupling to RAMP-1 leads to CGRP binding.32 RCP is
required for the transduction of the signal.33 Receptors for AM have
also been found in other human tumor cell lines.6 Secretion of the AM
peptide and expression of the AM receptors in PC-3 cells suggest an
autocrine role of AM in the growth inhibition and upregulation of
IL-13R2.
We have demonstrated by cDNA microarray analysis in the
present study that the overexpression of AM in PC-3 cells alters
the pattern of expression of 100 genes (approximately) involved in
cell cycle arrest and apoptosis, the formation of the cytoskeleton,
cell adhesion and the extracellular matrix, cytokines and transcrip-
tion factors. GADD45, IGF-BP6 and RUNX-3 are genes upregu-
lated by AM, which are related to cell growth arrest. The growth
arrest and DNA damage-inducible gene (GADD45) is a p53-
regulated gene involved in DNA repair, which has been found to
be upregulated in cells subjected to stress.34 UV irradiation and
overexpression of FGF2 lead to the upregulation of gene
GADD45.35 The ectopic overexpression of GADD45 results in cell
growth arrest and sensitization of cells to undergo apoptosis.35
RUNX-3 (which is overexpressed by AM) is another gene related
to cell cycle regulation. Lack of this gene causes gastric epithelial
hyperplasia and a reduced rate of apoptosis.36 In addition, RUNX-
3/ epithelial cells are less sensitive to TGF--mediated apopto-
sis and gastric cancer cells overexpressing RUNX-3 are signifi-
cantly less tumorigenic.36
Another gene upregulated by AM in PC-3 cells is the urokinase-
type plasminogen activator (u-PA), which participates in the degra-
dation of the extracellular matrix through the generation of plasmin
and mediates intracellular signaling through cAMP.37 u-PA is also
involved in proteolytic activation of growth factors, including TGF-
and FGF2.37 The serin proteinase inhibitor B2 (SERPIN-B2, also
called plasminogen activator inhibitor-2, or PAI-2), which was also
found upregulated by AM in our study, modulates the effect of
u-PA.38 PAI-2 inhibits cell migration and can modulate apoptosis.38
The dysregulation of the u-PA system in PC-3 cells due to the
overexpression of AM suggests that this peptide can induce changes
in motility, invasiveness and cellular signal transduction. These inter-
esting issues will be addressed in future studies.
IL-13R2 is a member of a cytokine receptor superfamily that
is internalized after binding to its ligand without mediating signal
transduction.25 IL-13R2 strongly increased its expression (ap-
proximately 4–25 times) in PC-3 cells transfected with the AM
gene. Since earlier studies showed that tumor cells expressing
IL-13R2 can be dramatically sensitized to the cytotoxic effects of
IL-13 cytotoxin, thus leading to cell death through apoptosis,39 we
decided to investigate this gene. Our earlier studies demonstrated
that tumor cells with low levels of IL-13R2 become very sensi-
tive to the cytotoxic effects of IL-13 cytotoxin after transient or
stable transfection of this receptor chain in vitro and in vivo.25
First, we have validated by RT-PCR the result obtained by mi-
croarray analysis. Second, we demonstrated that there is not only
an upregulation of IL-13R2 mRNA as a consequence of AM
overexpression, but also an upregulation of the protein, which
makes the cells highly sensitive to IL-13 cytotoxin. Third, we have
shown that upregulation of IL-13R2 mediated by AM can be
blocked by an anti-AM-specific antibody. The sensitization of
PC-3 cells to the cytotoxin IL13-PE38 is quite remarkable in some
of the clones with high expression of AM. Thus, the IC50 values of
inhibition for the clones AM15 and AM17 are closer to those
obtained for the highly sensitive cell PM-RCC (1–4 ng/mL),
which was used in our assay as a positive control. This is a striking
and novel finding, since no association between AM and the
IL-13R2 signaling pathway leading to toxin sensitization had
previously been identified. The molecular mechanism involved in
the regulation of AM and IL-13R2 expression remains undeter-
mined but is under current investigation. It is possible that AM
enhances the half-life of mRNA and/or protein and may interact
with IL-13R2 promoter to enhance its expression.
The fusion of toxins to IL-13 is a promising therapeutic ap-
proach for treating tumors and is currently in clinical trials for
brain tumors.40 The results presented in this study suggest that
novel strategies utilizing adrenomedullin signaling may be devel-
oped to increase the expression of IL-13R2, thereby sensitizing
tumors to IL-13R2-based therapies. Such approaches might in-
clude the direct delivery of AM using gene or protein systems to
increase expression of IL-13R2 followed by the targeting of
IL-13-based cytotoxins to the tumor cells.
Kawakami et al.25 reported that the chemokine IL-8 was upregu-
lated in MDA-MD-231 and PANC-1 cells as a result of IL-13R2
overexpression. Interestingly, our microarray results revealed that, in
addition to the overexpression of IL-13R2 in AM-overexpressing
cells, there is a concomitant increase in IL-8. IL-8 has been implicated
in tumor growth and metastases through its role in regulating angio-
genesis.41 AM has been shown to stimulate tumor angiogenesis
through induction of HIF-1.20 In addition, AM acts as a proangiogenic
factor in vivo in breast cancer42 and endometrial tumors.43 Therefore,
it will be of interest to examine interaction between AM, IL-8 and
IL-13R2 in relation to tumor angiogenesis.
In summary, numerous changes in gene expression associated
with the upregulation of adrenomedullin in prostate cancer cells
have been identified. This approach has provided additional insight
into genetic consequences of adrenomedullin function. We show a
novel AM-induced mechanism of tumor sensitization through the
upregulation of functional IL-13R2 chain, which is a target for
the specific recombinant chimeric cytotoxin IL13-PE38.
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TABLE III – IN VITRO INHIBITION OF COLONY FORMATION IN AM TRANSFECTED PC-3 CELL LINES BY THE TOXIN IL13-PE38
IL13-PE38 (ng/ml) Colonies (% control)
1
PC-3 PC-3 Mock PC-3 hAM3.2M PC-3 hAM3.2B PC-3 rAM15 PC-3 rAM17
0.1 96.0  3.2 92 4.6 74.0 4.8 68.0  1.6 70.3 2.1 68.0 5.2
1.0 95.2  4.8 94.2  3.2 61.2  2.8 56.2  2.3 48.2  3.1 51.6  3.6
10.0 98.2  5.6 95.2  4.0 36.1  2.4 31.3  0.9 22.4  1.2 19.2  1.7
100.0 84.6  6 82.0  7.0 10.8 0.6 9.2 1.6 6.5  1.7 12.0 1.9
1000.0 70.2 8.6 78.2 6.2 0.7 0.3 3.6 0.8 2.9 0.5 9.3 2.2
IC50 (ng/ml) 	1000 	1000 4 5.5 0.9 1.12
1Results are expressed as percentage of colonies formed by the treated cells compared to untreated control cells.
877ADRENOMEDULLIN REGULATION OF IL-13R2
References
1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics,
2001. CA Cancer J Clin 2001;51:15–36.
2. Kitamura K, Sakata J, Kangawa K, Kojima M, Matsuo H, Eto T. Cloning
and characterization of cDNA encoding a precursor for human ad-
renomedullin. Biochem Biophys Res Commun 1993;194:720–5.
3. Jime´nez N, Calvo A, Martinez A, Rosell D, Cuttitta F, Montuenga
LM. Expression of adrenomedullin and proadrenomedullin N-termi-
nal 20 peptide in human and rat prostate. J Histochem Cytochem
1999;47:1167–78.
4. Rocchi P, Boudouresque F, Zamora AJ, Muracciole X, Lechevallier
E, Martin PM, Ouafik L. Expression of adrenomedullin and peptide
amidation activity in human prostate cancer and in human prostate
cancer cell lines. Cancer Res 2001;61:1196–206.
5. Hinson JP, Kapas S, Smith DM. Adrenomedullin, a multifunctional
regulatory peptide. Endocr Rev 2000;21:138–67.
6. Cuttitta F, Pio R, Garayoa M, Zudaire E, Julian M, Elsasser TH,
Montuenga LM, Martinez A. Adrenomedullin functions as an impor-
tant tumor survival factor in human carcinogenesis. Microsc Res Tech
2002;57:110–9.
7. Caron KM, Smithies O. Multiple roles of adrenomedullin revealed by
animal models. Microsc Res Tech 2002;57:55–9.
8. Miller MJ, Martinez A, Unsworth EJ, Thiele CJ, Moody TW, Elsasser
T, Cuttitta F. Adrenomedullin expression in human tumor cell lines:
its potential role as an autocrine growth factor. J Biol Chem 1996;
271:23345–51.
9. Upton PD, Wharton J, Coppock H, Davie N, Yang X, Yacoub MH,
Ghatei MA, Polak JM, Bloom SR, Smith DM, Morrell NW. Ad-
renomedullin expression and growth inhibitory effects in distinct
pulmonary artery smooth muscle cell subpopulations. Am J Respir
Cell Mol Biol 2001;24:170–8.
10. Kapas S, Brown DW, Farthing PM, Hafi-Pavli E. Adrenomedullin has
mitogenic effects on human oral keratinocytes: involvement of cyclic
AMP. FEBS Lett 1997;418:287–90.
11. Szokodi I, Kinnunen P, Tavi P, Weckstrom M, Toth M, Ruskoaho H.
Evidence for cAMP-independent mechanisms mediating the effects of
adrenomedullin, a new inotropic peptide. Circulation 1998;97:1062–70.
12. Ali N, Yousufzai SY, Abdel-Latif AA. Activation of particulate
guanylate cyclase by adrenomedullin in cultured SV-40 transformed
cat iris sphincter smooth muscle (SV-CISM-2) cells. Cell Signal
2000;12:491–8.
13. Mazzocchi G, Albertin G, Andreis PG, Neri G, Malendowicz LK,
Champion HC, Bahceliogla M, Kadowitz PJ, Nussdorfer GG. Distri-
bution, functional role, and signaling mechanism of adrenomedullin
receptors in the rat adrenal gland. Peptides 1999;20:1479–87.
14. Andreis PG, Neri G, Prayer-Galetti T, Rossi GP, Gottardo G, Malen-
dowicz LK, Nussdorfer GG. Effects of adrenomedullin on the human
adrenal glands: an in vitro study. J Clin Endocrinol Metab 1997;82:
1167–70.
15. Tomoda Y, Isumi Y, Katafuchi T, Minamino N. Regulation of ad-
renomedullin secretion from cultured cells. Peptides 2001;22:1783–94.
16. Eto T, Kato J, Kitamura K. Regulation of production and secretion of
adrenomedullin in the cardiovascular system. Regul Pept 2003;112:61–9.
17. Sugo S, Minamino N, Shoji H, Kangawa K, Kitamura K, Eto T,
Matsuo H. Interleukin-1, tumor necrosis factor and lipopolysaccharide
additively stimulate production of adrenomedullin in vascular smooth
muscle cells. Biochem Biophys Res Commun 1995;207:25–32.
18. Isumi Y, Minamino N, Kubo A, Nishimoto N, Yoshizaki K, Yoshioka
M, Kangawa K, Matsuo H. Adrenomedullin stimulates interleukin-6
production in Swiss 3T3 cells. Biochem Biophys Res Commun 1998;
244:325–31.
19. Elsasser TH, Sartin JL, Martinez A, Kahl S, Montuenga L, Pio R,
Fayer R, Miller M, Cuttitta F. Underlying disease stress augments
plasma and tissue adrenomedullin (AM) responses to endotoxin:
colocalized increases in AM and inducible nitric oxide synthase
within pancreatic islets. Endocrinology 1999;140:5402–11.
20. Garayoa M, Martinez A, Lee S, Pio R, An WG, Neckers L, Trepel J,
Montuenga LM, Ryan H, Johnson R, Gassmann M, Cuttitta F. Hy-
poxia-inducible factor-1 (HIF-1) upregulates adrenomedullin expres-
sion in human tumor cell lines during oxygen deprivation: a possible
promotion mechanism of carcinogenesis. Mol Endocrinol 2000;14:
848–62.
21. Abasolo I, Yang L, Xiao W, Haleem R, Pı´o R, Cuttitta F, Montuenga
LM, Kozlowski JM, Calvo A, Wang Z. Overexpression of adrenomedul-
lin gene markedly inhibits proliferation of PC3 prostate cancer cells in
vitro and in vivo. Mol Cell Endocrinol 2003;199:179–87.
22. Joshi BH, Kawakami K, Leland P, Puri RK. Heterogeneity in inter-
leukin-13 receptor expression and subunit structure in squamous cell
carcinoma of head and neck: differential sensitivity to chimeric fusion
proteins comprised of interleukin-13 and a mutated form of Pseudo-
monas exotoxin. Clin Cancer Res 2002;8:1948–56.
23. Desai KV, Kavanaugh CJ, Calvo A, Green JE. Chipping away at
breast cancer: insights from microarray studies of human and mouse
mammary cancer. Endocr Relat Cancer 2002;9:207–20.
24. Murata T, Obiri NI, Puri RK. Human ovarian-carcinoma cell lines
express IL-4 and IL-13 receptors: comparison between IL-4- and
IL-13-induced signal transduction. Int J Cancer 1997;70:230–40.
25. Kawakami K, Kawakami M, Snoy PJ, Husain SR, Puri RK. In vivo
overexpression of IL-13 receptor alpha2 chain inhibits tumorigenicity
of human breast and pancreatic tumors in immunodeficient mice. J
Exp Med 2001;194:1743–54.
26. Ouafik L, Sauze S, Boudouresque F, Chinot O, Delfino C, Fina F,
Vuaroqueaux V, Dussert C, Palmari J, Dufour H, Grisoli F, Casellas
P, et al. Neutralization of adrenomedullin inhibits the growth of
human glioblastoma cell lines in vitro and suppresses tumor xenograft
growth in vivo. Am J Pathol 2002;160:1279–92.
27. Puri RK, Leland P, Obiri NI, Husain SR, Kreitman RJ, Haas GP,
Pastan I, Debinski W. Targeting of interleukin-13 receptor on human
renal cell carcinoma cells by a recombinant chimeric protein com-
posed of interleukin-13 and a truncated form of Pseudomonas exo-
toxin A (PE38QQR). Blood 1996;87:4333–9.
28. Husain SR, Obiri NI, Gill P, Zheng T, Pastan I, Debinski W, Puri RK.
Receptor for interleukin 13 on AIDS-associated Kaposi’s sarcoma
cells serves as a new target for a potent Pseudomonas exotoxin-based
chimeric toxin protein. Clin Cancer Res 1997;3:151–6.
29. Derst C, Engel H, Grzeschik K, Daut J. Genomic structure and
chromosome mapping of human and mouse RAMP genes. Cytogenet
Cell Genet 2000;90:115–8.
30. Minty A, Chalon P, Derocq JM, Dumont X, Guillemot JC, Kaghad M,
Labit C, Leplatois P, Liauzun P, Miloux B. Interleukin-13 is a new
human lymphokine regulating inflammatory and immune responses.
Nature 1993;362:248–50.
31. Maini A, Hillman G, Haas GP, Wang CY, Montecillo E, Hamzavi F,
Pontes JE, Leland P, Pastan I, Debinski W, Puri RK. Interleukin-13
receptors on human prostate carcinoma cell lines represent a novel
target for a chimeric protein composed of IL-13 and a mutated form
of Pseudomonas exotoxin. J Urol 1997;158(3 Pt 1):948–53.
32. Foord SM, Marshall FH. RAMPs: accessory proteins for seven
transmembrane domain receptors. Trends Pharmacol Sci 1999;20:
184–7.
33. Evans BN, Rosenblatt MI, Mnayer LO, Oliver KR, Dickerson IM.
CGRP-RCP, a novel protein required for signal transduction at calci-
tonin gene-related peptide and adrenomedullin receptors. J Biol Chem
2000;275:31438–43.
34. Pedeux R, Lefort K, Cuenin C, Cortes U, Kellner K, Dore JF,
Nakazawa H. Specific induction of gadd45 in human melanocytes and
melanoma cells after UVB irradiation. Int J Cancer 2002;98:811–6.
35. Dell’Era P, Coco L, Ronca R, Sennino B, Presta M. Gene expression
profile in fibroblast growth factor 2-transformed endothelial cells.
Oncogene 2002;21:2433–40.
36. Li QL, Ito K, Sakakura C, Fukamachi H, Inoue K, Chi XZ, Lee KY,
Nomura S, Lee CW, Han SB, Kim HM, Yamamoto H, et al. Causal
relationship between the loss of RUNX3 expression and gastric can-
cer. Cell 2002;109:113–24.
37. Andreasen PA, Kjoller L, Christensen L, Duffy MJ. The urokinase-
type plasminogen activator system in cancer metastasis: a review. Int
J Cancer 1997;72:1–22.
38. Dear AE, Medcalf RL. The urokinase-type-plasminogen-activator recep-
tor (CD87) is a pleiotropic molecule. Eur J Biochem 1998;252:185–93.
39. Kawakami M, Kawakami K, Puri RK. Intratumor administration of
interleukin 13 receptor-targeted cytotoxin induces apoptotic cell death
in human malignant glioma tumor xenografts. Mol Cancer Ther
2002;1:999–1007.
40. Barth S. hIL-13-PE38QQR. NeoPharm. Curr Opin Invest Drugs 2001;
2:1309–13.
41. Lee LF, Hellendall RP, Wang Y, Haskill JS, Mukaida N, Matsushima
K, Ting JP. IL-8 reduced tumorigenicity of human ovarian cancer in
vivo due to neutrophil infiltration. J Immunol 2000;164:2769–75.
42. Martinez A, Vos M, Guedez L, Kaur G, Chen Z, Garayoa M, Pio R,
Moody T, Stetler-Stevenson WG, Kleinman HK, Cuttitta F. The
effects of adrenomedullin overexpression in breast tumor cells. J Natl
Cancer Inst 2002;94:1226–37.
43. Oehler MK, Hague S, Rees MC, Bicknell R. Adrenomedullin pro-
motes formation of xenografted endometrial tumors by stimulation of
autocrine growth and angiogenesis. Oncogene 2002;21:2815–21.
878 GONZALEZ-MORENO ET AL.
